Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.（BLCM）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · BLCM · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
0
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Bellicum Pharmaceuticals, Inc.内部人在过去近12个月买卖活动混合。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
BLCM 季度内部人买卖趋势
BLCM 内幕交易卖出 · BLCM 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
BLCM 高管卖出股份 · BLCM 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Nov 22, 2023 | BAKER BROS. ADVISORS LP 10 percent owner | Other | 1,941,607 | $194 | Form 4 |
| Nov 22, 2023 | BAKER BROS. ADVISORS LP 10 percent owner | Other | 174,742 | $17 | Form 4 |
| Jan 3, 2023 | Daly James M Director | Option | 60,414 | — | Form 4 |
| Jan 3, 2023 | DAVIS STEPHEN Director | Option | 74,739 | — | Form 4 |
| Jan 3, 2023 | Huber Reid M Director | Option | 87,196 | — | Form 4 |
| Jan 3, 2023 | Stonehouse Jon P Director | Option | 121,452 | — | Form 4 |
| Jan 3, 2023 | Klimovsky Judith V Director | Option | 60,414 | — | Form 4 |
| Sep 1, 2022 | Klimovsky Judith V Director | Option | 35,082 | — | Form 4 |
| Sep 1, 2022 | DAVIS STEPHEN Director | Option | 43,400 | — | Form 4 |
| Sep 1, 2022 | Daly James M Director | Option | 35,082 | — | Form 4 |
| Sep 1, 2022 | Huber Reid M Director | Option | 46,489 | — | Form 4 |
| Sep 1, 2022 | Stonehouse Jon P Director | Option | 60,580 | — | Form 4 |
| Jan 4, 2022 | Huber Reid M Director | Option | 19,494 | — | Form 4 |
| Jan 4, 2022 | BROWN JAMES F Director | Option | 28,384 | — | Form 4 |
| Jan 4, 2022 | Stonehouse Jon P Director | Option | 21,504 | — | Form 4 |
| Jan 4, 2022 | Daly James M Director | Option | 809 | — | Form 4 |
| Jan 4, 2022 | Daly James M Director | Option | 13,568 | — | Form 4 |
| Jan 4, 2022 | Klimovsky Judith V Director | Option | 566 | — | Form 4 |
| Jan 4, 2022 | Klimovsky Judith V Director | Option | 14,036 | — | Form 4 |
| Jan 4, 2022 | DAVIS STEPHEN Director | Option | 18,715 | — | Form 4 |
| May 29, 2020 | Ward Shane Sr VP and Chief Legal SO | Other | 107 | $816 | Form 4 |
| Mar 17, 2020 | Fair Richard A. President and CEO · Director | Purchase | 5,000 | $20K | Form 4 |
| Jan 3, 2020 | Williams Rosemary Y. VP, Finance & PAO | Option | 781 | — | Form 4 |
Fair Richard A.
President and CEO · Director
日期
Mar 17
股数
5,000
均价
$4.00
总金额
$20K
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 BLCM 内幕交易
BLCM 内幕交易
Bellicum Pharmaceuticals, Inc.（BLCM）内幕交易数据来源于公司内部人（包括BLCM）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。BLCM内部人近期买卖活动混合，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Bellicum Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
BLCM 内幕交易 · 5个问题Bellicum Pharmaceuticals, Inc.（BLCM）的内部人包括高管和董事，如BLCM等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026